Asset
LIGRITINIB
ARCUS BIOSCIENCES INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06120075 | phase1 | completed | 2024-01-19 | 2026-04-29 | Arcus Biosciences, Inc. | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies |
| NCT06004921 | phase1 | completed | 2023-10-16 | 2024-02-23 | Arcus Biosciences, Inc. | A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.